Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/JCI138745 http://scihub22266oqcxt.onion/10.1172/JCI138745 32254064!7259988!32254064     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Invest 2020 ; 130 (6): 2757-2765 Nephropedia Template TP {{tp|p=32254064|t=2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19 |pdf=|usr=}}{{32254064}} gab.com Text Deployment of convalescent plasma for the prevention and treatment of COVID-19 JO: J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=32254064 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., "convalescent") plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-up is brought underway to mobilize this critical resource. Twit Text FOAVip Deployment of convalescent plasma for the prevention and treatment of COVID-19 ????J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=32254064 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32254064 #FOAvip English Wikipedia <ref>{{Cite pmid|32254064}}</ref> Deployment of convalescent plasma for the prevention and treatment of COVID-19 #MMPMID32254064 Bloch EM; Shoham S; Casadevall A; Sachais BS; Shaz B; Winters JL; van Buskirk C; Grossman BJ; Joyner M; Henderson JP; Pekosz A; Lau B; Wesolowski A; Katz L; Shan H; Auwaerter PG; Thomas D; Sullivan DJ; Paneth N; Gehrie E; Spitalnik S; Hod EA; Pollack L; Nicholson WT; Pirofski LA; Bailey JA; Tobian AA J Clin Invest 2020[Jun]; 130 (6): 2757-2765 PMID32254064show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., "convalescent") plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-up is brought underway to mobilize this critical resource. |*Betacoronavirus/immunology[MESH] |Antibodies, Viral/administration & dosage/blood/therapeutic use[MESH] |Blood Donors[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/blood/epidemiology/immunology/*prevention & control/*therapy[MESH] |Humans[MESH] |Immunization, Passive/adverse effects[MESH] |Investigational New Drug Application[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/epidemiology/*prevention & control/*therapy[MESH] |Risk Assessment[MESH] |SARS-CoV-2[MESH] |United States[MESH]Deployment of convalescent plasma for the prevention and treatment of (epmc).pdf DeepDyve Pubget Overpricing